Dupilumab Shows Long-time period Efficacy in EoE

Dupilumab Shows Long-time period Efficacy in EoE

Knowledge from the 28-week extension of the LIBERTY EoE TREET fragment 3 clinical trial showed that the anti–interleukin-4/IL-13 antibody dupilumab resulted in lengthy-time period enchancment in eosinophil depend, histology, and affected person-reported indicators of eosinophilic esophagitis (EoE) out to 28…